Medications

People with IBD often have sleep problems and ongoing inflammation; melatonin could help both sleep and clinical disease activity, which may improve quality of life. The review suggests potential benefit but is not...

If true, the tripartite circuit model helps explain why some patients respond to therapies that target one pathway while others do not — because other nodes in the loop may sustain disease.

This study gives real-world comparative data on two biologic options (vedolizumab vs anti-TNFα) used early in the treatment course for Crohn’s disease, which may help patients and clinicians weigh effectiveness and...

A subcutaneous option for infliximab could simplify maintenance therapy, reduce infusion visits, and change how drug levels and accompanying immunomodulators are managed — issues many people with IBD and their clinicians...

Patients and clinicians choosing among advanced therapies for ulcerative colitis may consider infection-related hospitalization risk as one factor; this study suggests lower risk with ustekinumab versus TNF antagonists...

Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Infliximab. The original article is from Inflammatory Bowel Diseases.

Predicting who will relapse after stopping anti-TNF drugs could help avoid unnecessary flares or unnecessary ongoing treatment. A biopsy-based transcriptomic test could be a useful decision tool if validated.

Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Mirikizumab. The original article is from Journal of the Canadian Association of...

Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Ustekinumab. The original article is from The American journal of gastroenterology.

First-person accounts of Crohn's or colitis can help others recognize severe symptoms, the emotional toll of chronic gut disease, and that surgery can be part of a pathway to symptom relief for some people.

Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease, Vedolizumab, and Anti Integrin. The original article is from Journal of the Canadian Association of...

Based on the title and source metadata, this appears to be a case report related to Crohn's disease, Inflammatory bowel disease, and Medications. The original article is from Gastroenterology report.

Children with newly diagnosed IBD are increasingly started on advanced therapies early after diagnosis and are receiving fewer corticosteroids.

This study links a neutrophil protein (ANXA3) to both ulcerative colitis and ischaemic stroke and suggests a compound (ginsenoside Rb1) can bind ANXA3 and reduce neutrophil hyperactivation in lab tests — a potential...

Launches of adalimumab and ustekinumab could expand local access to two widely used biologic treatments for Crohn’s disease and ulcerative colitis. Wider availability may affect treatment options and logistics for people...

Researchers are exploring ways to deliver steroids like budesonide more precisely to the intestine while avoiding stomach leakage and sudden drug release. If translated to humans, such a formulation could improve local...

This study identifies a new molecular pathway (JAK2–STAT4–AK4–mtDNA) linked to inflammatory macrophage activity in experimental colitis and presents a plant-derived alkaloid mixture (TAMR) that modulates that pathway....

Patients and clinicians choosing induction therapy for moderate‑to‑severe ulcerative colitis may find comparative efficacy and safety data useful, especially when head‑to‑head trials are limited. The review highlights...

This review summarises the rapidly changing drug landscape for Crohn’s disease and ulcerative colitis, including newly approved biologics and small molecules and several emerging therapies that may affect future...

Researchers are exploring ways to deliver steroids to the inflamed gut while lowering systemic side effects; a nanoparticle carrier that protects the epithelium and concentrates drug in the colon could, if translated,...

This study describes use of upadacitinib for children and young adults with highly refractory IBD and reports that most patients stayed on therapy at 1 year; a small subgroup treated with combined upadacitinib and...

Based on the title and source metadata, this appears to be a case report related to Crohn's disease, Inflammatory bowel disease, and Ustekinumab. The original article is from Intestinal research.

Perianal fistulas are common and burdensome in Crohn’s disease; this large multicenter Korean study quantifies high rates of complex fistulas, frequent recurrence, and suggests biologic therapy is associated with fewer...

Cure8 could only read part of this source from Intestinal Research, so this card uses cautious topic tags instead of a full summary. It is tagged for Ulcerative colitis, Crohn's disease, and Inflammatory bowel disease.

Based on the title and source metadata, this appears to be a systematic review or meta analysis related to Inflammatory bowel disease, Crohn's disease, and Biosimilars. The original article is from Arquivos de...

Based on the title and source metadata, this appears to be a basic science related to Inflammatory bowel disease and Research and clinical trials. The original article is from Research in pharmaceutical sciences.

A pediatric trial of budesonide rectal foam could provide evidence about a locally acting steroid option for children with distal ulcerative colitis. Trial results may affect treatment choices for pediatric distal...

Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Inflammatory bowel disease, and Medications. The original article is from hmpgloballearningnetwork.com.

For people with Crohn’s disease, this study suggests that biologic drugs reduce inflammation in both proximal and distal small bowel to a similar degree, as measured by capsule endoscopy.

Postoperative pain control choices after ileocecectomy could affect Crohn's flare risk and opioid exposure. A pediatric center-level analysis found no association between ketorolac and flares and suggested reduced opioid...

For people with UC who do not respond to tacrolimus, adding infliximab may induce remission and reduce the short-term need for colectomy. The findings point to a potential rescue strategy and an option to transition to...

Patients and clinicians choosing a next biologic after prior biologic failure may find evidence here that effectiveness is broadly similar between vedolizumab and ustekinumab overall, with potential differences depending...

Bowel urgency is a common, distressing symptom in ulcerative colitis that matters for quality of life. This analysis indicates vedolizumab may reduce urgency and that early improvement is linked to better clinical and...

People with IBD on biologic therapies may benefit from accurate drug-level testing to guide treatment decisions.

An oral diabetes drug (empagliflozin) may reduce a toxic metabolite linked to neutropenia and inflammation in GSD Ib, and this case report suggests it helped an adult patient’s blood counts, infections risk, and...

The study suggests adding a structured 16-week exclusive enteral nutrition plan to ustekinumab treatment may improve short- and medium-term clinical and endoscopic outcomes for adults with moderate-to-severe Crohn’s...

This review explains how new drug classes and mechanism-focused strategies may change how IBD is treated, which could affect choices for patients who have not responded to existing therapies and inform discussions about...

Many people with IBD use over-the-counter pain relievers without realizing they can irritate the gut. This article explains when ibuprofen or naproxen might raise risks for people with Crohn’s disease or ulcerative...

GLP-1 and dual GIP/GLP-1 agonists are being studied as treatments that could help people with IBD who also have obesity or metabolic problems by reducing weight and inflammation without clearly worsening IBD. This could...

The study presents a preclinical strategy to concentrate an existing antihistamine drug in the colon and reduce systemic exposure, which could improve local efficacy and safety for IBD treatment if later validated in...

The review compiles trial and real-world safety data for upadacitinib in IBD and highlights monitoring needs and infection risks (notably herpes zoster), which are directly relevant when choosing or managing JAK...

The work aims to improve colon-targeted delivery of an aminosalicylate (balsalazide) to boost local drug levels and protect the drug from gastric degradation—potentially relevant to people with ulcerative colitis looking...

If you or someone you care for uses or may use VELSIPITY (etrasimod) for ulcerative colitis, local manufacturing and priority review in China could improve drug supply, availability, and potentially lower costs. The...

Based on the title and source metadata, this appears to be a case report related to Crohn's disease, Infliximab, and Anti-TNF. The original article is from Polish archives of internal medicine.

Positive results and a planned Phase 2b study suggest ontunisertib is progressing in development for fibrostenosing Crohn’s disease — a condition with limited targeted therapies for intestinal fibrosis.

Patients with refractory IBD or those not fully responding to single targeted therapies may be interested because ACT aims to control multiple inflammatory pathways and could offer improved symptom and endoscopic...

Cure8 found this source from drugstorenews.com, but the page could not be read reliably yet. It is tagged for Adalimumab, Biosimilars, and Anti-TNF. Open the original article for the full details.

This report describes open‑label extension data for ontunisertib, an investigational oral drug being tested specifically for fibrostenosing Crohn’s disease.